Stockscreener 앱 받기
19.86
1.15%
0.225
시간 외 거래:
19.55
-0.31
-1.56%
전일 마감가:
$19.64
열려 있는:
$19.7
하루 거래량:
2.24M
Relative Volume:
1.68
시가총액:
$2.42B
수익:
$460.48M
순이익/손실:
$142.80M
주가수익비율:
16.83
EPS:
1.18
순현금흐름:
$221.79M
1주 성능:
-5.97%
1개월 성능:
-4.29%
6개월 성능:
-13.28%
1년 성능:
+8.52%
1일 변동 폭
$19.48
$20.08
1주일 범위
$19.15
$22.53
52주 변동 폭
$17.58
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
19.86 | 2.66B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Catalyst Pharmaceuticals reaffirms $545M-$565M 2025 revenue guidance while accelerating FIRDAPSE oncology expansion - MSN
Catalyst Pharma Receives Buy Rating and Price Target of $34.00 from Bank of America Securities Analyst Jason Gerberry. - AInvest
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Catalyst Pharmaceuticals Reports Strong Q2 2025 Earnings - TipRanks
Catalyst Pharma Updates Guidelines for SCLC Treatment - TipRanks
Transcript : Catalyst Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: Catalyst Pharmaceuticals Q2 2025 beats EPS forecast - Investing.com
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years - 富途牛牛
Catalyst Pharmaceutical Partners Inc. Exceeds Q2 Earnings ExpectationsNews and Statistics - IndexBox
Catalyst Pharmaceuticals shares rise 1.70% premarket after Q2 revenue and adjusted EPS beat expectations. - AInvest
Catalyst Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Catalyst Pharmaceuticals reports Q2 EPS 68c, consensus 54c - TipRanks
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Catalyst Pharma Reports Record Q2 2025 Financial Results - TipRanks
Catalyst Pharmaceuticals earnings beat by $0.29, revenue topped estimates - Investing.com Canada
Catalyst Pharmaceuticals Q2 revenue, adjusted EPS beats expectations, reaffirms 2025 revenue guidance - MarketScreener
Catalyst Pharmaceuticals Reports Record Second Quarter and - GlobeNewswire
Catalyst Pharmaceuticals Announces Inclusion of VGCC Antibody Testing and Amifampridine in NCCN Guidelines for Small Cell Lung Cancer-Associated LEMS - Quiver Quantitative
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing - GlobeNewswire
90% of SCLC Patients Miss LEMS Diagnosis: NCCN Updates Guidelines with Critical Testing Protocol - Stock Titan
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? - MSN
Catalyst Pharmaceutics To Report Q2 Earnings: What's In The Cards? - Barchart.com
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - simplywall.st
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors - GlobeNewswire
Catalyst Pharma Appoints Dr. Curran to Board - TipRanks
Catalyst Pharmaceuticals Appoints Dr. Daniel Curran to Board of Directors - Quiver Quantitative
Ex-Takeda Rare Disease Chief Joins Catalyst Pharmaceuticals Board to Drive Strategic Growth - Stock Titan
What are the technical indicators suggesting about Catalyst Pharmaceuticals Inc.Skyrocketing returns - Jammu Links News
What are analysts’ price targets for Catalyst Pharmaceuticals Inc. in the next 12 monthsMarket-leading capital gains - Jammu Links News
What makes Catalyst Pharmaceuticals Inc. stock price move sharplyGet real-time alerts on high-potential stocks - Jammu Links News
Why is Catalyst Pharmaceuticals Inc. stock attracting strong analyst attentionDiscover stocks with superior performance - Jammu Links News
How does Catalyst Pharmaceuticals Inc. compare to its industry peersRealize consistent double-digit growth - Jammu Links News
What are the latest earnings results for Catalyst Pharmaceuticals Inc.Game-changing capital returns - Jammu Links News
How strong is Catalyst Pharmaceuticals Inc. company’s balance sheetFree Daily Trading Room Entry - Jammu Links News
When is Catalyst Pharmaceuticals Inc. stock expected to show significant growthUnlock rapid growth potential in your portfolio - Jammu Links News
What catalysts could drive Catalyst Pharmaceuticals Inc. stock higher in 2025Exceptional stock performance - Jammu Links News
What is the dividend policy of Catalyst Pharmaceuticals Inc. stockOutstanding stock performance - Jammu Links News
Is Catalyst Pharmaceuticals Inc. stock overvalued or undervaluedUnrivaled growth potential - Jammu Links News
Does Catalyst Pharmaceuticals Inc. stock perform well during market downturnsStock Strategy Insights For Fast Growth - Jammu Links News
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? - Yahoo Finance
How many analysts rate Catalyst Pharmaceuticals Inc. as a “Buy”Free Stock Review Backed By Experts - Jammu Links News
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Can Traders Expect Breakout From Catalyst Pharmaceuticals Inc. This WeekSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen enviable returns of 404% over the past five years - Yahoo Finance
Zacks.com featured highlights Catalyst Pharmaceuticals, SunOpta, Gambling.com and Orion Group - The Globe and Mail
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):